UnknownPhase 2NCT03181815

Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

Studying Acute myeloid leukemia with 11q23 abnormalities

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Principal Investigator
Liang Wang, M.D.
Sun Yat-sen Univerisity
Intervention
Cladribine(drug)
Enrollment
48 enrolled
Eligibility
15-75 years · All sexes
Timeline
20162019

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03181815 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia with 11q23 abnormalities

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia with 11q23 abnormalities

← Back to all trials